The biopharmaceutical sector continues to seek new opportunities to leverage mRNA technology and thrives on strategic alliances, which allow for cross-functional sharing of knowledge, skills, and experience across different disciplines to truly advance mRNA drugs to patients faster. Hear first-hand how biopharma business development leaders and investors are taking their time to evaluate novel innovations and building new collaborations.

• Leveraging the past experiences of recent deals, collaborations and acquisitions in mRNA-LNP platforms to inform future risk and decision-making strategies
• Where do you see potential white spaces that mRNA can fill within this sector or indications more specifically?
• What data is required and how far does an asset have to progress towards future investment or acquisition success?